新疆百花村医药集团股份有限公司 证券代码：600721 证券简称：百花医药 公告编号：2022-045 新疆百花村医药集团股份有限公司关于参加 2022 年新疆辖区 投资者网上集体接待日暨上市公司业绩说明会活动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 为便于广大投资者更深入全面地了解公司情况、发展战略、经营状况、融资 计划、股权激励、可持续发展等投资者所关心的问题，公司定于 2022 年 6 月 24 日参加由新疆上市公司协会联合深圳市全景网络有限公司组织开展的 2022 年新 疆辖区上市公司投资者网上集体接待日活动。现将有关事项公告如下： 本次集体接待日活动将在深圳市全景网络有限公司提供的网上平台，采取网 络远程的方式举行，投资者可以登录全景网"投资者关系互动平台"网站 （http://ir.p5w.net/）或关注微信公众号：全景财经（微信号：p5w2012），参与 公司本次投资者集体接待日活动，活动时间为 2022 年 6 月 24 日下午（星期五） 15:00 至 17:30。 出席本次集体接待日的人员有：公司董事长郑彩红、轮值总经理荆 ...

Financial Performance - The company's operating revenue for Q1 2022 was CNY 58,796,482.88, representing a year-on-year increase of 24.40%[5] - The net profit attributable to shareholders of the listed company was CNY 1,372,156.64, up 28.00% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 945,756.27, an increase of 122.20% year-on-year[5] - Basic earnings per share were CNY 0.0037, an increase of 27.59% year-on-year[5] - Total operating revenue for Q1 2022 reached ¥58,796,482.88, a 24.3% increase from ¥47,264,446.74 in Q1 2021[17] - Net profit for Q1 2022 was ¥1,378,890.58, representing a 27.3% increase compared to ¥1,083,387.72 in Q1 2021[17] - Total profit for Q1 2022 was ¥2,005,268.37, up from ¥1,763,077.94 in Q1 2021, reflecting a growth of 13.7%[17] Cash Flow and Assets - The net cash flow from operating activities was negative at CNY -12,682,485.50, reflecting a decrease of 6.89% compared to the previous year[5] - Cash flow from operating activities showed a net outflow of ¥12,682,485.50 in Q1 2022, slightly improved from a net outflow of ¥13,620,328.17 in Q1 2021[19] - The company's cash and cash equivalents decreased to RMB 49,289,567.66 from RMB 86,884,849.85, representing a decline of about 43.3%[13] - The company reported cash and cash equivalents of ¥49,289,567.66 at the end of Q1 2022, down from ¥41,785,041.34 at the end of Q1 2021[20] Expenses and Investments - The company's research and development expenses increased by 282.09% compared to the same period last year, indicating a significant investment in R&D[7] - Research and development expenses rose significantly to ¥4,354,071.54 in Q1 2022, compared to ¥1,139,542.38 in Q1 2021, marking an increase of 282.5%[17] - Sales expenses rose by 130.88% year-on-year, primarily due to the expansion of the sales team for business growth[7] - The company experienced a decrease in investment income, reporting a loss of ¥684,735.13 in Q1 2022 compared to a gain of ¥43,802.21 in Q1 2021[17] Assets and Liabilities - The total assets at the end of the reporting period were CNY 980,924,866.39, a slight decrease of 0.14% from the end of the previous year[5] - As of March 31, 2022, the total current assets amounted to RMB 474,176,742.25, a slight increase from RMB 468,093,854.92 at the end of 2021, reflecting a growth of approximately 1.2%[13] - Total liabilities as of March 31, 2022, were RMB 293,293,913.94, a decrease from RMB 296,060,953.02 at the end of 2021, reflecting a reduction of approximately 0.9%[15] - The total equity of the company was RMB 687,630,952.45, slightly up from RMB 686,252,061.87, showing an increase of about 0.2%[15] - Non-current assets totaled RMB 506,748,124.14, down from RMB 514,219,159.97, reflecting a decrease of approximately 1.5%[14] - The company’s total assets were RMB 980,924,866.39, slightly lower than RMB 982,313,014.89 at the end of 2021, indicating a decrease of about 0.1%[14] - The company’s contract liabilities increased to RMB 90,640,179.23 from RMB 85,727,394.43, representing a growth of approximately 5.0%[15] Government Support - The company received government subsidies amounting to CNY 388,403.94, which are closely related to its normal business operations[7]

Financial Performance - The company's operating revenue for Q1 2022 was CNY 58,796,482.88, representing a year-on-year increase of 24.40%[5] - The net profit attributable to shareholders for the same period was CNY 1,372,156.64, up 28.00% compared to the previous year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 122.20% to CNY 945,756.27[5] - Basic earnings per share for the quarter were CNY 0.0037, an increase of 27.59% year-on-year[5] - Total operating revenue for Q1 2022 reached ¥58,796,482.88, a 24.3% increase from ¥47,264,446.74 in Q1 2021[15] - Net profit for Q1 2022 was ¥1,378,890.58, representing a 27.3% increase compared to ¥1,083,387.72 in Q1 2021[15] - The basic earnings per share for Q1 2022 was ¥0.0037, up from ¥0.0029 in Q1 2021[16] Cash Flow and Assets - The net cash flow from operating activities was negative at CNY -12,682,485.50, reflecting a decrease of 6.89%[5] - Cash flow from operating activities showed a net outflow of ¥12,682,485.50, an improvement from a net outflow of ¥13,620,328.17 in Q1 2021[17] - The company reported a decrease in cash and cash equivalents to CNY 49,289,567.66 from CNY 86,884,849.85, a decline of approximately 43.0%[11] - Cash and cash equivalents at the end of Q1 2022 totaled ¥49,289,567.66, compared to ¥41,785,041.34 at the end of Q1 2021[18] Research and Development - The company's research and development expenses increased by 282.09% compared to the same period last year, indicating a significant investment in R&D[7] - Research and development expenses rose significantly to ¥4,354,071.54, up 282.5% from ¥1,139,542.38 in Q1 2021[15] - The company plans to continue focusing on R&D and market expansion strategies to drive future growth[15] Liabilities and Equity - The total liabilities decreased to CNY 293,293,913.94 from CNY 296,060,953.02, representing a reduction of approximately 0.9%[13] - The company's total equity increased to CNY 687,630,952.45 as of March 31, 2022, compared to CNY 686,252,061.87 at the end of 2021, showing a growth of about 0.2%[13] - The total liabilities to equity ratio as of March 31, 2022, was approximately 0.43, indicating a relatively stable leverage position[13] Inventory and Receivables - Inventory as of March 31, 2022, was CNY 203,632,250.60, up from CNY 194,047,820.84, marking an increase of approximately 4.1%[11] - Accounts receivable rose to CNY 21,180,170.24 from CNY 17,759,114.68, reflecting an increase of about 19.3%[11] Government Subsidies and Expenses - The company received government subsidies amounting to CNY 388,403.94, which were closely related to its normal business operations[7] - Sales expenses rose by 130.88%, primarily due to the expansion of the sales team at Lihua Bio[7]

Financial Performance - In 2021, the company achieved operating revenue of CNY 281.35 million, a year-on-year increase of 232.84% compared to CNY 84.53 million in 2020[20]. - The net profit attributable to shareholders of the listed company for 2021 was CNY 59.83 million, a significant turnaround from a net loss of CNY 319.77 million in 2020, representing an increase of 118.71%[20]. - The company reported a net cash flow from operating activities of CNY 34.72 million in 2021, compared to a negative cash flow of CNY 23.28 million in 2020, marking a 249.14% improvement[20]. - The total assets of the company at the end of 2021 were CNY 982.31 million, a slight increase of 0.78% from CNY 974.68 million at the end of 2020[20]. - The net assets attributable to shareholders of the listed company increased by 10.02% to CNY 681.30 million at the end of 2021, up from CNY 619.26 million at the end of 2020[20]. - The basic earnings per share for 2021 were CNY 0.1595, a recovery from a loss of CNY 0.8202 per share in 2020, reflecting an increase of 119.45%[21]. - The company’s weighted average return on equity improved to 9.22% in 2021, up by 50.80 percentage points from -41.58% in 2020[21]. - The company reported a net profit attributable to shareholders for the reporting period was CNY 59.8271 million, achieving a turnaround from loss to profit, primarily due to a debt restructuring gain of CNY 47.5566 million from an agreement with Western Oasis[22]. - The total revenue for the year was CNY 281.3530 million, a year-on-year increase of 232.84% from CNY 84.5304 million[30]. - The company’s other income increased significantly by 926.89% to CNY 49.56 million, primarily due to the transfer of a 30% stake in a subsidiary[56]. Research and Development - The company reported significant growth in pharmaceutical research and clinical study contracts, with an increase in projects obtaining production licenses and passing consistency evaluations compared to the previous year[21]. - The company completed 300+ generic drug R&D applications for over 200 pharmaceutical companies, including more than 50 of the top 100 pharmaceutical companies in China[29]. - The company applied for 15 new invention patents during the reporting period, with 4 patents authorized in China and 1 in the United States[32]. - Pharmaceutical R&D revenue reached CNY 140.14 million, an increase of 546.62% year-on-year, with costs decreasing by 51.01%, resulting in a gross margin of 44.43%[60]. - Clinical trial revenue was CNY 106.70 million, up 215.46% year-on-year, with costs increasing by 46.67%, leading to a gross margin of 15.05%[61]. - The company has developed over 350 new drug technologies and obtained more than 100 Chinese and international PCT technology invention patents[48]. - The company is focused on developing gene markers for liver cancer detection, enhancing its product portfolio in oncology[114]. Market Strategy and Expansion - The company aims to enhance its core competitiveness in pharmaceutical R&D and clinical research, focusing on strategic acquisitions to expand its industry chain[91]. - The company plans to upgrade its R&D services to high-end generic drug development, leveraging existing technical advantages[91]. - The company is expanding its clinical services from generic drugs to innovative drug development, focusing on high-value-added services[92]. - The company plans to strengthen its technical capabilities and service capacity through the establishment of a comprehensive "investment, financing, and research" cooperation channel[94]. - The company is exploring potential mergers and acquisitions to further enhance its product portfolio and market reach, with a focus on strategic partnerships[157]. - The company plans to expand its market presence in Southeast Asia, targeting a 30% increase in international sales by 2023[156]. Corporate Governance and Compliance - The company has held 12 board meetings and 6 shareholder meetings in 2021, ensuring effective governance and decision-making[102]. - The company has not identified any significant differences in governance compared to regulatory requirements, ensuring compliance with laws and regulations[109]. - The company has taken measures to maintain independence from its controlling shareholders, ensuring no significant impact from related business activities[109]. - The company has committed to transparency in disclosing related party transactions to protect the interests of all shareholders[155]. - The company will ensure that any necessary related party transactions are conducted in accordance with legal and regulatory requirements[154]. - The company has established a robust investor relations management framework to facilitate effective communication with stakeholders[108]. Human Resources and Management - The company has a professional technical team of 722 people, with over 90% holding a bachelor's degree or above, and 143 holding master's or doctoral degrees[29]. - The number of R&D personnel was 586, making up 81.16% of the total workforce[73]. - The company has a diverse management team with extensive experience in finance, pharmaceuticals, and clinical research, enhancing its strategic capabilities[113]. - The total pre-tax remuneration for directors and senior management during the reporting period amounted to 6.99 million yuan[112]. - The company has a structured governance framework, with clear roles and responsibilities for its board members and management team[118]. Financial Management and Investments - The company has engaged in structured deposits totaling ¥26,500,000 and non-principal guaranteed bank wealth management products amounting to ¥27,900,000[177]. - The company has a commitment to continue its wealth management plans in the future, reflecting a proactive approach to asset management[178]. - The company has a series of structured deposits with annualized returns ranging from 1.48% to 3.08%, with total expected returns of ¥42,786.52 from various investments[178]. - The company has successfully recovered all amounts from its wealth management products, indicating effective cash management strategies[178]. - The company has a total of ¥6,297,615.37 in guarantees outstanding to subsidiaries as of the reporting period[175]. Future Outlook - The company aims for a revenue and net profit growth of no less than 20% in 2022 compared to the previous year[94]. - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 10% to 12%[160]. - The company has set a revenue target of 1.5 billion yuan for 2022, indicating an ambitious growth strategy with an expected increase of 25%[156].

Financial Performance - The company's operating revenue for the third quarter reached ¥64,582,728.22, representing a year-on-year increase of 470.95%[3] - The net profit attributable to shareholders was ¥4,945,568.20, reflecting a significant increase of 196.08% compared to the same period last year[3] - The basic earnings per share (EPS) for the quarter was ¥0.0132, up 189.19% year-on-year[3] - The net profit attributable to shareholders increased by 231.07% to CNY 54.89 million, compared to a net loss of CNY 41.88 million in the same period last year, primarily due to increased sales and gains from equity transfer and debt restructuring[8] - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 105.85% to CNY 5.96 million, compared to a net loss of CNY 10.19 million in the same period last year, mainly driven by increased sales[8] - Basic earnings per share rose by 237.37% to CNY 0.1463, compared to a loss of CNY 0.1065 in the same period last year, reflecting the increase in sales[8] - Operating profit for the first three quarters of 2021 was ¥47,478,367.11, compared to a loss of ¥101,253,622.51 in the first three quarters of 2020, indicating a turnaround in profitability[17] - Net profit for the first three quarters of 2021 was ¥54,931,343.97, a substantial improvement from a net loss of ¥41,881,540.74 in the same period of 2020[17] Assets and Liabilities - Total assets at the end of the reporting period were ¥966,826,158.11, a decrease of 0.81% from the end of the previous year[4] - Total liabilities decreased to ¥287,729,927.25 as of September 30, 2021, from ¥350,519,430.13 at the end of 2020, reflecting a reduction of approximately 17.9%[15] - The company's total assets as of September 30, 2021, amounted to ¥966,826,158.11, slightly down from ¥974,684,317.02 at the end of 2020[15] - The company's equity attributable to shareholders increased to ¥674,159,273.98 as of September 30, 2021, up from ¥619,263,889.76 at the end of 2020, marking an increase of about 8.9%[15] Cash Flow - Cash flow from operating activities showed a net outflow of ¥7,698,340.41, a decline of 484.50% compared to the previous year[3] - The net cash flow from investing activities decreased by 135.24% to a net outflow of CNY 11.68 million, compared to a net inflow of CNY 33.15 million in the same period last year, mainly due to increased cash expenditures for purchasing bank wealth management products[8] - The net cash flow from financing activities increased by 290.72% to CNY 1.27 million, compared to a net outflow of CNY 0.66 million in the same period last year, primarily due to bank loans from the subsidiary[8] - The net cash flow from operating activities for the first three quarters of 2021 was -7,698,340.41 RMB, compared to 2,002,156.36 RMB in the same period of 2020, indicating a decline in operational performance[20] - The company reported a cash balance of 27,503,292.51 RMB at the end of the reporting period, a decrease from 85,610,987.20 RMB at the end of the same period in 2020[21] - The company experienced a net decrease in cash and cash equivalents of -18,112,147.95 RMB, contrasting with an increase of 34,487,824.38 RMB in the same period of 2020[21] Research and Development - Research and development expenses increased to ¥3,253,800, representing a full increase compared to the same period last year, driven by innovation drug research[7] - Research and development expenses for the first three quarters of 2021 were reported at ¥3,253,778.41, indicating ongoing investment in innovation[17] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 10,503[10] - The largest shareholder, Xinjiang Hualing Industry and Trade Group Co., Ltd., holds 21.20% of the shares, totaling 79,525,087 shares[10] - The company implemented an employee stock option incentive plan, granting 12.1 million stock options to 162 participants[12] Sales and Expenses - The company’s sales expenses increased by 30.48% to ¥437,630, primarily due to hiring more sales personnel to expand market reach[7] - The company's total operating costs for the first three quarters of 2021 were ¥166,930,022.40, down from ¥186,031,966.71 in the same period of 2020, reflecting a cost reduction strategy[17]

Financial Performance - The company's operating revenue for the first half of 2021 was approximately ¥119.80 million, representing a 20.97% increase compared to ¥99.03 million in the same period last year[16]. - The net profit attributable to shareholders for the first half of 2021 was approximately ¥49.95 million, a significant turnaround from a loss of ¥36.73 million in the same period last year, marking a 235.98% increase[16]. - The basic earnings per share for the first half of 2021 was ¥0.1332, compared to a loss of ¥0.0917 per share in the same period last year, reflecting a 245.26% improvement[17]. - The weighted average return on net assets for the first half of 2021 was 7.75%, a recovery from -3.99% in the same period last year, indicating improved profitability[18]. - The company achieved total revenue of CNY 119.80 million in the first half of 2021, an increase of 20.97% compared to the same period last year[31]. - Net profit attributable to shareholders reached CNY 49.95 million, a significant increase of 235.98% year-on-year, primarily due to a share transfer agreement that generated CNY 43.50 million in gains[31]. Assets and Liabilities - The company's net assets attributable to shareholders increased by 8.07% to approximately ¥669.21 million from ¥619.26 million at the end of the previous year[16]. - The total assets of the company showed a slight increase of 0.31%, reaching approximately ¥977.66 million compared to ¥974.68 million at the end of the previous year[16]. - The company's total assets as of June 30, 2021, were CNY 977.66 million, a 0.31% increase from the beginning of the year, while total liabilities decreased by 13.41% to CNY 303.52 million[32]. - The company's total liabilities amounted to ¥91,281,881.36, a decrease from ¥131,704,959.57 in the previous year[110]. - The company's total liabilities were CNY 303,518,812.04, down from CNY 350,519,430.13, representing a decrease of approximately 13.4%[106]. Cash Flow - The company reported a net cash flow from operating activities of approximately -¥15.43 million, an improvement of 63.35% from -¥42.08 million in the same period last year[16]. - The net cash flow from operating activities improved by 63.35%, reaching approximately -15.43 million, attributed to increased cash receipts from sales[44]. - Cash inflow from operating activities was CNY 102,782,500.84, a decrease of 9.3% from CNY 113,443,981.07 in the same period last year[118]. - The net cash flow from investment activities was -CNY 3,631,528.79, compared to CNY 6,797,574.97 in the same period last year[119]. Market and Industry Trends - The global pharmaceutical R&D outsourcing ratio is expected to increase from approximately 39.5% in 2019 to 49.3% by 2023, indicating a growing trend in the CRO industry[27]. - The Chinese CRO market is projected to grow significantly, with the industry size expected to reach $43.2 billion by 2023, reflecting a compound annual growth rate of about 21.1% from 2019[27]. - The increasing demand for high-quality generic drugs and innovative drug development in China is driving the growth of the CRO industry[25]. Business Operations - The company's main business focuses on drug development and technology transfer, covering almost all disease areas including oncology, hypertension, and diabetes[23]. - The CRO service model aims to save time and costs for pharmaceutical companies by providing specialized outsourced services throughout the drug development process[24]. - The company aims to expand its service offerings in drug discovery, CMC development, clinical trials, and regulatory submissions through a one-stop outsourcing model[22]. - The company has established a nationwide clinical trial center network, enhancing its capability to conduct I-IV phase clinical trials efficiently[29]. - The company emphasizes a one-stop CRO service advantage, covering the entire drug development process from discovery to registration[28]. Employee and Management - The company employs a highly qualified team of 636 professionals, with 88% being research and development personnel, ensuring high-quality service delivery[28]. - The company implemented an employee stock option incentive plan, granting 12.10 million stock options to 162 employees during the reporting period[41]. - The management team has shown a positive trend in personal shareholding, with several executives increasing their holdings during the reporting period[100]. Regulatory and Compliance - The company has not reported any non-operational fund occupation by controlling shareholders or related parties during the reporting period[4]. - The company has committed to fair operations and compliance with disclosure obligations in any necessary related party transactions[77]. - The company confirmed that it will not engage in any business activities that compete with its listed operations, ensuring no direct or indirect competition[75]. Strategic Initiatives - The company is focusing on expanding its market presence and exploring new strategies, including potential mergers and acquisitions[68]. - The company has set a three-year shareholder return plan for 2021-2023[68]. - The company plans to issue non-public A-shares to raise funds, with a feasibility report on the use of raised funds presented[68]. Risks and Challenges - The company faces increasing market competition from both domestic and international CRO companies, which may pressure pricing and profitability[59]. - Regulatory risks are significant in the pharmaceutical R&D and manufacturing sectors, requiring the company to adapt to changing policies[60]. - The complexity of pharmaceutical R&D projects poses risks of contract termination and rising costs as the company expands its services[61]. - The ongoing impact of COVID-19, particularly the Delta variant, may adversely affect the company's operations[64].

新疆百花村股份有限公司 证券代码：600721 证券简称：*ST 百花 公告编号：2021- 052 新疆百花村股份有限公司关于参加 2021 年新疆辖区 投资者网上集体接待日暨上市公司业绩说明会活动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 为便于广大投资者更深入全面地了解公司情况、发展战略、经营状况、融资 计划、股权激励、可持续发展等投资者所关心的问题，公司定于 2021 年 6 月 18 日下午 15:00 至 17:30 参加由新疆上市公司协会联合深圳市全景网络有限公司组 织开展的 2021 年新疆辖区上市公司投资者网上集体接待日活动。现将有关事项 公告如下： 本次集体接待日活动将在深圳市全景网络有限公司提供的网上平台，釆取网 络远程的方式举行，投资者可以登录全景网"投资者关系互动平台"网站 （http://ir.p5w.net/）或关注微信公众号：全景财经（微信号：p5w2012）,参与公 司本次投资者集体接待日活动，活动时间为 2021 年 6 月 18 日（星期五）15:00 至 17:30。 出席本次集体接待日的人员有：公司董事长 ...

Financial Performance - Net profit attributable to shareholders was CNY 1,071,993.40, representing a decline of 26.31% year-on-year[5] - Operating revenue for the period was CNY 47,264,446.74, an increase of 1.33% compared to the same period last year[5] - Basic earnings per share decreased by 19.44% to CNY 0.0029[5] - The company reported a net profit excluding non-recurring items of CNY 425,633.74, a significant improvement compared to a loss in the previous year[5] - The company reported a significant decrease in investment income for the current period, amounting to CNY 0.04 million, a reduction of 91.65% compared to the same period last year[15] - Operating profit for Q1 2021 was CNY 1,561,321.42, compared to CNY 1,024,934.61 in Q1 2020, indicating a growth of 52.2%[29] - The net profit for Q1 2021 was ¥614,431.60, a decrease of 30.7% from ¥885,802.02 in Q1 2020[33] - The operating profit for Q1 2021 was ¥841,495.74, down 38.2% from ¥1,362,642.26 in Q1 2020[32] - The total profit for Q1 2021 was ¥857,985.01, down 37.0% from ¥1,362,642.26 in Q1 2020[32] Cash Flow - The net cash flow from operating activities improved by 35.86%, reaching -CNY 13,620,328.17[5] - Net cash flow from operating activities for the current period was CNY -13.62 million, an improvement of CNY 7.61 million compared to the same period last year, mainly due to reduced cash payments to employees and lower tax payments[16] - The cash inflow from operating activities in Q1 2021 was ¥48,027,178.52, a decrease of 9.4% from ¥52,743,048.39 in Q1 2020[35] - The company's total cash inflow from operating activities was significantly impacted by increased payments to employees and other operational expenses, totaling 24,705,412.95 RMB in Q1 2021[38] - The total cash inflow from operating activities was 12,572,025.93 RMB, up from 4,524,293.84 RMB in the same period last year, reflecting a 178% increase[38] - The cash outflow for operating activities reached 27,802,445.08 RMB, compared to 5,116,316.98 RMB in Q1 2020, marking a 444% increase in cash outflows[38] Assets and Liabilities - Total assets at the end of the reporting period were CNY 960,827,824.81, a decrease of 1.42% compared to the end of the previous year[5] - Total liabilities as of March 31, 2021, were CNY 293.13 million, a decrease from CNY 308.24 million at the end of 2020[20] - Total assets as of March 31, 2021, amounted to CNY 714,984,479.82, slightly down from CNY 715,717,492.79 at the end of 2020[24] - Total liabilities as of March 31, 2021, were CNY 130,357,515.00, a decrease from CNY 131,704,959.57 at the end of 2020[25] - Shareholders' equity totaled CNY 584,626,964.82 as of March 31, 2021, compared to CNY 584,012,533.22 at the end of 2020, showing a slight increase[25] Shareholder Information - The total number of shareholders at the end of the reporting period was 9,702[11] - The largest shareholder, Xinjiang Hualing Industrial Trade Group Co., Ltd., held 21.20% of the shares[11] Expenses - Sales expenses for the current period were CNY 1.14 million, a decrease of CNY 0.19 million or 14.15% compared to the same period last year, primarily due to reduced sales business expenses[15] - R&D expenses for the current period were CNY 1.14 million, an increase compared to the same period last year due to expenses related to innovative drug research by a subsidiary[15] - Research and development expenses for Q1 2021 were CNY 1,139,542.38, indicating ongoing investment in innovation[29] Cash and Cash Equivalents - Cash and cash equivalents at the end of the period were CNY 41.79 million, a decrease of CNY 3.83 million or 8.40% from the beginning of the period, mainly due to reduced cash retention for operations[13] - Cash and cash equivalents decreased to CNY 4,388,814.55 from CNY 14,580,472.06 at the end of 2020, indicating a significant reduction in liquidity[23] - The total cash and cash equivalents at the end of Q1 2021 were 41,785,041.34 RMB, down from 51,123,162.82 RMB at the beginning of the quarter[37] - The company reported a cash and cash equivalents net decrease of 3,830,399.12 RMB in Q1 2021, compared to a decrease of 26,271,804.68 RMB in Q1 2020[37]

Financial Performance - The company's net profit for 2020 was -339,536,904.66 RMB, with a cumulative distributable profit of -2,018,041,645.09 RMB, leading to no cash dividend distribution for the year [4]. - The operating revenue for 2020 was 84,530,414.24 RMB, a decrease of 67.74% compared to 262,017,718.33 RMB in 2019 [17]. - The net profit attributable to shareholders for 2020 was -320 million RMB, indicating a shift from profit to loss primarily due to revenue decline and rising costs [40]. - Basic earnings per share for 2020 was -0.8202 CNY, a decrease of 1,053.72% compared to 0.0860 CNY in 2019 [19]. - The weighted average return on equity decreased by 45.26 percentage points to -41.58% in 2020 from 3.68% in 2019 [19]. - The company reported a gross loss of CNY 13.69 million for 2020 [185]. Assets and Liabilities - Total assets decreased by 24.51% to 974,684,317.02 RMB from 1,291,205,717.74 RMB in 2019 [18]. - The net asset attributable to shareholders decreased by 35.13% to 619,263,889.76 RMB from 954,695,566.45 RMB in 2019 [18]. - The company's current assets decreased to CNY 440,459,673.45 from CNY 599,439,079.01, reflecting a reduction of approximately 26.6% [197]. - Total liabilities increased slightly to CNY 350,519,430.13 from CNY 336,510,151.29, indicating a growth of about 4.0% year-over-year [198]. - The total liabilities to total assets ratio stands at approximately 36.0%, indicating a moderate level of leverage [198]. Cash Flow - The company reported a net cash flow from operating activities of -23,281,213.51 RMB, a decline of 242.60% compared to -6,795,414.33 RMB in 2019 [18]. - The company reported a net cash flow from investing activities of ¥33,625,074.48, a significant increase of 176.13% compared to -¥44,167,040.78 in the previous period [75]. - The net cash flow from financing activities decreased compared to the previous year, primarily due to repayment of bank loans [58]. Research and Development - The company has a strong R&D capability with over 700 professional service team members, including 158 with doctoral or master's degrees [37]. - The total R&D expenditure for the year was CNY 6,114,512.78, accounting for 7.23% of the company's revenue [71]. - R&D expenses increased to CNY 6.11 million, reflecting a focus on innovative drug development [57]. - The company is focusing on building a proprietary technology pipeline for innovative drugs, particularly in niche areas, to meet diverse market demands [91]. Market and Industry Trends - The CRO industry is expected to grow significantly, with global outsourcing of pharmaceutical R&D projected to increase from 39.5% in 2019 to 49.3% by 2023 [35]. - The Chinese pharmaceutical R&D service market is forecasted to grow from approximately 20.1 billion USD in 2019 to 43.2 billion USD by 2023, with a compound annual growth rate of about 21.1% [35]. - The pharmaceutical industry is experiencing a shift towards innovative drug development, with over 3,000 companies globally engaged in new drug research, indicating a growing market for CRO services in China [87]. Corporate Governance and Compliance - The company received a standard unqualified audit report from Sigma Accounting Firm [6]. - The company has not engaged in any non-operating fund occupation by controlling shareholders or related parties [5]. - The company has not violated any decision-making procedures for providing guarantees [5]. - The company has committed to avoiding any business activities that compete with its listed company and its subsidiaries [109]. Shareholder and Equity Information - The total share capital at the end of 2020 was 375,134,355 shares, a decrease of 6.31% from 400,386,394 shares in 2019 [18]. - The company did not distribute any cash dividends or stock bonuses in the years 2018, 2019, and 2020, with net losses of RMB 675.29 million, RMB 34.38 million, and RMB 319.77 million respectively [107]. - The total number of ordinary shareholders increased from 9,588 to 10,065 during the reporting period, representing a growth of approximately 5% [140]. Employee and Management Information - The company employed a total of 770 staff, with 42 in the parent company and 728 in major subsidiaries [163]. - The technical personnel accounted for 620 out of the total 770 employees, indicating a strong focus on technical expertise [163]. - The total pre-tax remuneration for the board members during the reporting period amounted to 452.99 million yuan [154]. Risks and Challenges - The company is at risk of delisting as it reported a negative net profit and operating revenue below 100 million RMB, triggering the delisting risk warning as per the Shanghai Stock Exchange regulations [5]. - The company faces competition from both established international players and emerging domestic CRO firms, necessitating a strategic response to maintain its market position [101].

Financial Performance - Operating revenue for the first nine months was CNY 81,620,014.02, down 59.66% year-on-year[7] - Net profit attributable to shareholders was a loss of CNY 41,881,540.74, representing a decrease of 184.05% compared to the same period last year[7] - Basic and diluted earnings per share were both CNY -0.1065, a decline of 185.54% year-on-year[8] - The company reported a net loss of CNY 101,908,886.13 attributable to shareholders, a decline of 333.08% year-on-year[7] - The company reported a net loss of 23.01 million yuan in the third quarter, with a revenue drop of 66.83% compared to the same period last year, primarily due to contract terminations[15] - Total revenue for Q3 2020 was -17,410,053.23 CNY, compared to 69,197,985.80 CNY in Q3 2019, indicating a significant decline[34] - Net profit for Q3 2020 was -5,147,302.38 CNY, compared to a net profit of 12,224,706.18 CNY in Q3 2019, representing a year-over-year decline of 142.1%[35] Cash Flow - Cash flow from operating activities for the first nine months was CNY 2,002,156.36, an increase of 105.23% compared to the same period last year[7] - Net cash flow from operating activities was 2.00 million yuan, an increase of 4,029.54 million yuan compared to the same period last year, primarily due to receiving 73.05 million yuan in compensation and arbitration fees[22] - Net cash flow from investing activities was 33.15 million yuan, an increase of 6,420.78 million yuan year-on-year, mainly due to a reduction of 67.20 million yuan in cash outflow for purchasing bank wealth management products[22] - Net cash flow from financing activities was -0.66 million yuan, a decrease of 467.08 million yuan compared to the same period last year, primarily due to a reduction in cash received from borrowings[23] - The net cash flow from operating activities for the first nine months of 2020 was ¥2,002,156.36, a recovery from a negative cash flow of ¥38,293,210.29 in the same period of 2019[43] - Total cash inflow from operating activities was 136,311,122.18 RMB, compared to 49,097,058.55 RMB in the first three quarters of 2019, indicating a significant increase[45] Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,279,393,041.50, a decrease of 0.91% compared to the end of the previous year[7] - Total liabilities were 381.85 million yuan, an increase from 336.51 million yuan at the end of 2019[29] - The company's total equity attributable to shareholders was 897.54 million yuan, down from 954.70 million yuan at the end of 2019[30] - Total liabilities increased to 133,064,497.91 CNY in Q3 2020, compared to 91,109,367.03 CNY in Q3 2019, marking an increase of approximately 46%[33] - The company's total equity as of Q3 2020 was 963,921,252.95 CNY, up from 923,945,764.05 CNY in Q3 2019, showing a growth of about 4.3%[33] Operational Changes - The company terminated 29 pharmaceutical R&D contracts, resulting in a revenue reduction of 59.70 million yuan and a profit decrease of 65.99 million yuan[17] - The company plans to adjust its strategic layout towards a combination of generic and innovative drug development in response to market changes[19] - The company aims to enhance its business team and improve customer service to mitigate the impact of contract terminations and revenue declines[20] - The company has not reported any new product launches or technological advancements during this period, indicating a potential area for future growth[54] Financial Ratios and Metrics - The weighted average return on equity decreased by 9.87 percentage points to -4.56%[8] - Financial expenses surged to 17.03 million yuan, an increase of 5581.65% from 0.30 million yuan, mainly due to the recognition of unconfirmed financing costs[20] - The company's total liabilities to equity ratio indicates a leverage position that may require monitoring for financial stability[53] Other Income and Expenses - Other income decreased to 1.32 million yuan, down 43.01% from 2.32 million yuan, primarily due to reduced government subsidies[21] - The company incurred a credit impairment loss of 5,719,269.51 CNY in Q3 2020, compared to a recovery of -667,996.07 CNY in Q3 2019, indicating a significant deterioration in credit quality[35] - The company reported a financial expense of ¥15,693,623.42 in Q3 2020, significantly higher than ¥178,217.36 in Q3 2019[38]